As of 2026-09-21, the EV/EBITDA ratio of Cardiff Oncology Inc (CRDF) is -2.08. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Cardiff's latest enterprise value is 98.04 mil USD. Cardiff's TTM EBITDA according to its financial statements is -47.07 mil USD. Dividing these 2 quantities gives us the above Cardiff EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.4x - 16.6x | 15.9x |
| Forward P/E multiples | 17.7x - 19.4x | 18.6x |
| Fair Price | (10.60) - (9.93) | (10.33) |
| Upside | -873.7% - -825.1% | -853.8% |
| Date | EV/EBITDA |
| 2026-09-18 | -2.08 |
| 2026-09-17 | -1.97 |
| 2026-09-16 | -2.05 |
| 2026-09-15 | -2.03 |
| 2026-09-14 | -1.98 |
| 2026-09-11 | -1.82 |
| 2026-09-10 | -1.82 |
| 2026-09-09 | -1.55 |
| 2026-09-08 | -1.64 |
| 2026-09-04 | -1.62 |
| 2026-09-03 | -1.60 |
| 2026-09-02 | -1.57 |
| 2026-09-01 | -1.52 |
| 2026-08-31 | -1.46 |
| 2026-08-28 | -1.37 |
| 2026-08-27 | -1.45 |
| 2026-08-26 | -1.44 |
| 2026-08-25 | -1.50 |
| 2026-08-24 | -1.47 |
| 2026-08-21 | -1.27 |
| 2026-08-20 | -1.32 |
| 2026-08-19 | -1.30 |
| 2026-08-18 | -1.28 |
| 2026-08-17 | -1.31 |
| 2026-08-14 | -1.41 |
| 2026-08-13 | -1.44 |
| 2026-08-12 | -1.46 |
| 2026-08-11 | -1.55 |
| 2026-08-10 | -1.52 |
| 2026-08-07 | -1.46 |
| 2026-08-06 | -1.41 |
| 2026-08-05 | -1.40 |
| 2026-08-04 | -1.35 |
| 2026-08-03 | -1.36 |
| 2026-07-31 | -1.23 |
| 2026-07-30 | -1.22 |
| 2026-07-29 | -1.16 |
| 2026-07-28 | -1.17 |
| 2026-07-27 | -1.20 |
| 2026-07-24 | -1.19 |
| 2026-07-23 | -1.20 |
| 2026-07-22 | -1.24 |
| 2026-07-21 | -1.21 |
| 2026-07-20 | -1.20 |
| 2026-07-17 | -1.27 |
| 2026-07-16 | -1.26 |
| 2026-07-15 | -1.29 |
| 2026-07-14 | -1.98 |
| 2026-07-13 | -2.05 |
| 2026-07-10 | -2.02 |